ARENA PHARMACEUTICALS is in a rapidly changing global market, where we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to discover and develop medicines for patients, and relentlessly execute until it’s done.
Our GI research portfolio includes etrasimod, a once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, currently in Phase 3 for ulcerative colitis and in Phase 2b for Crohn’s disease and olorinab, an oral, highly selective, peripherally acting, full agonist of the cannabinoid receptor 2 (CB2), currently in Phase 2b for IBS visceral pain.
These are investigational compounds, not approved for use in any country.
To learn more about Arena, please visit us at www.arenapharm.com.
ARENA – Care More. Act Differently.